IC
AGIO icon

Ikarian Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Ikarian Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,200
Closed -$3.73M – 163
2025
Q4 		$3.73M Sell
137,200
-12,800
-9% -$449K 0.29% 73
2025
Q3 		$6.02M Buy
+150,000
New +$5.64M 0.61% 39
2021
Q2 		– Sell
-125,000
Closed -$6.46M – 214
2021
Q1 		$6.46M Hold
125,000
– – 0.22% 103
2020
Q4 		$5.42M Buy
+125,000
New +$4.94M 0.24% 88
2020
Q1 		– Sell
-50,000
Closed -$2.39M – 152
2019
Q4 		$2.39M Buy
+50,000
New +$1.89M 0.39% 58

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Ikarian Capital's AGIO Position: Q1 2026 in Review

Ikarian Capital sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 115,489 shares — an estimated $3.14M sold.

Ikarian Capital first reported a position in AGIO in Q3 2025 and held it in 2 quarters. The position peaked at $5.1M in Q3 2025. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Ikarian Capital reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 115,489 Agios Pharmaceuticals shares in Q1 2026, an estimated $3.14M.
  • Ikarian Capital first reported a position in Agios Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Ikarian Capital's Agios Pharmaceuticals position peaked at $5.1M in Q3 2025.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.